ClinVar Miner

Submissions for variant NM_000199.5(SGSH):c.1139A>G (p.Gln380Arg) (rs144143780)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000666337 SCV000790612 pathogenic Mucopolysaccharidosis, MPS-III-A 2017-04-04 criteria provided, single submitter clinical testing
GeneDx RCV000309724 SCV000329515 pathogenic not provided 2018-08-30 criteria provided, single submitter clinical testing The Q380R pathogenic variant has been detected in 9% of alleles from individuals with MPS IIIA from the Netherlands and has been associated with a severe phenotype (Weber et al., 1997; Valstar et al., 2010). The Q380R variant was not observed with any significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project. Therefore, based on the currently available information, Q380R is considered a pathogenic variant.
Integrated Genetics/Laboratory Corporation of America RCV000666337 SCV000920206 pathogenic Mucopolysaccharidosis, MPS-III-A 2018-09-24 criteria provided, single submitter clinical testing Variant summary: SGSH c.1139A>G (p.Gln380Arg) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.3e-05 in 246122 control chromosomes. c.1139A>G has been reported in the literature in multiple individuals affected with Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome A). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating SGSH enzyme activity and showed the variant results in <10% of normal activity (Knottnerus_2017). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Invitae RCV000666337 SCV000954324 pathogenic Mucopolysaccharidosis, MPS-III-A 2018-12-17 criteria provided, single submitter clinical testing This sequence change replaces glutamine with arginine at codon 380 of the SGSH protein (p.Gln380Arg). The glutamine residue is weakly conserved and there is a small physicochemical difference between glutamine and arginine. This variant is present in population databases (rs144143780, ExAC 0.02%). This variant has been observed in combination with other pathogenic variants in SGSH in several individuals affected with mucopolysaccharidosis Type IIIA (PMID: 9285796, 21061399, 29023963). ClinVar contains an entry for this variant (Variation ID: 279891). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. For these reasons, this variant has been classified as Pathogenic.
Mayo Clinic Genetic Testing Laboratories,Mayo Clinic RCV000309724 SCV000801897 likely pathogenic not provided 2017-05-15 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.